AXSM News and Press, Axsome Therapeutics Inc. From 01/25/24

2024-01-25 23:11:51 ET Summary Lundbeck's new CEO has laid out a plan to maximize the value of the company's current portfolio, reorganize R&D, and deploy capital towards growth-sustaining M&A. The company aims to maximize the value of its current portfolio, particularly f...

2024-01-25 12:51:33 ET More on Axsome Therapeutics Axsome: Show Me Another Company With Such A Stack Of Catalysts Axsome Therapeutics: Positive Q3, We Like The Launch Success Story Axsome Therapeutics: Costs Outpacing Auvelity Growth (Rating Downgrade) New AD...

NEW YORK, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced it will report its financial results for the fourth quarter and...

2024-01-21 13:30:00 ET Pharmaceutical companies would be wise to pay attention to developing new treatments for ADHD as there is a demand for improved drugs in the space. Currently, the medications of choice for the condition are stimulant drugs, such as Takeda's ( NYSE: TAK ) V...

2024-01-16 09:30:02 ET Piper Sandler analyst issues BUY recommendation for AXSM on January 16, 2024 10:00AM ET. The previous analyst recommendation was Buy. AXSM was trading at $84.79 at issue of the analyst recommendation. The overall analyst consensus : BUY. Curren...

2024-01-16 09:30:01 ET H.C. Wainwright analyst issues UNDERPERFORM recommendation for AXSM on January 16, 2024 10:00AM ET. The previous analyst recommendation was Underperform. AXSM was trading at $84.79 at issue of the analyst recommendation. The overall analyst consens...

Preliminary total 4Q and full year 2023 net product revenue of $71 million and $204 million, respectively Auvelity preliminary 4Q and full year 2023 net product sales of $49 million and $130 million, respectively Sunosi preliminary 4Q and full year 2023 net product revenue of $2...

2024-01-03 07:00:00 ET Summary The biotech industry experienced a challenging year in 2023 due to a rising 10-year Treasury yield. In 2024, the 10-year yield should favorably support biotech stocks. Promising advancements in weight loss drugs, neuroscience, oncology, and gene ...

2024-01-03 05:20:00 ET Growth stocks get the designation because they have the potential to generate life-changing gains for investors. Some even do so in a relatively short time frame. Finding proper growth stocks generally involves determining which companies can turn the above-average gr...

2024-01-01 06:50:00 ET No person knows for sure what the future will hold for stocks in the new year. However, it can be fun to attempt to predict what might happen. Three Fool.com contributors have done just that. Here's why they think that Axsome Therapeutics (NASDAQ: AXSM) ...